The Journal of Practical Medicine >
Protective effect of LncRNA MEG3 on diabetic retinopathy in rats by regulating COX⁃2/PGE2/VEGF signaling pathway
Received date: 2025-02-10
Online published: 2025-05-20
Objective To investigate the protective effect of LncRNA MEG3 on the retina in early-stage diabetic rats through regulation of the COX-2/PGE2/VEGF signaling pathway. Methods 50 male SD rats of SPF grade were selected for the study. Among them, 10 rats were assigned to the control group, while 40 rats were used to establish diabetic retinopathy models. A total of 32 rats successfully underwent modeling and were subsequently divided into four groups (n = 8 per group): model group, negative control group, MEG3 overexpression group, and MEG3 overexpression + COX-2 inhibitor group. Histopathological changes, vascular permeability, glucose and lipid metabolism, inflammatory factors, oxidative stress indices, PGE2 levels, as well as the relative mRNA and protein expression levels of COX-2 and VEGF were evaluated in each group. Results Compared with the control group, HDL-C, CAT, GSH-PX, and SOD levels were significantly decreased, whereas the mRNA and protein expression levels of vascular permeability, TG, TC, LDL-C, IL-6, IL-1β, TNF-α, MDA, PGE2, COX-2, and VEGF were significantly increased in the model group (P < 0.05). Compared with the negative control group, HDL-C, CAT, GSH-PX, and SOD levels were significantly increased in the MEG3 overexpression group, while the mRNA and protein expression levels of vascular permeability, TG, TC, LDL-C, IL-6, IL-1β, TNF-α, MDA, PGE2, COX-2, and VEGF were significantly decreased (P < 0.05). Compared with the MEG3 overexpression group, HDL-C, CAT, GSH-PX, and SOD levels were further increased in the MEG3 overexpression + COX-2 inhibitor group, and the mRNA and protein expression levels of vascular permeability, TG, TC, LDL-C, IL-6, IL-1β, TNF-α, MDA, PGE2, COX-2, and VEGF were further decreased (P < 0.05). Conclusion LncRNA MEG3 is capable of regulating the COX-2/PGE2/VEGF pathway, enhancing glucose and lipid metabolism in rats, suppressing the expression of inflammatory factors, attenuating stress responses, and alleviating diabetic retinopathy.
Mei CHEN , Zongzhi LI , Xuewei QIN , Limin WANG , LI ZHENG . Protective effect of LncRNA MEG3 on diabetic retinopathy in rats by regulating COX⁃2/PGE2/VEGF signaling pathway[J]. The Journal of Practical Medicine, 2025 , 41(9) : 1319 -1326 . DOI: 10.3969/j.issn.1006-5725.2025.09.007
| 1 | 许瑶,娄静,赵峰. LncRNA-XIST/miR-137/Notch1在糖尿病视网膜病变患者血清和玻璃体中的表达及机制[J]. 实用医学杂志,2020,36(17):2409-2414. |
| 2 | 王思琦,卢雪,金香子,等. 线粒体ND4基因12026 A→G突变与糖尿病视网膜病变视网膜中央动脉血流动力学变化的关系[J]. 实用医学杂志,2022,38(14):1743-1746. |
| 3 | LI H, LIU C, ZHANG J, et al. The association of homocysteine level with the risk of diabetic nephropathy and diabetic retinopathy in NHANES[J]. Acta Diabetol, 2023, 60(7):907-916. doi:10.1007/s00592-023-02075-2 |
| 4 | 王艳平,刘含军. 长链非编码RNA(LncRNA)母系表达基因3(MEG3)对糖尿病视网膜病变大鼠模型视网膜血管内皮细胞凋亡的影响[J]. 眼科新进展,2023,43(1):18-24. |
| 5 | 张庆龙,赵宁,李芷鉴. 红景天苷通过COX-2/PGE2/VEGF通路对糖尿病大鼠视网膜病变的影响[J]. 中国医科大学学报,2023,52(8):731-735. |
| 6 | 蒲洁琨,姜爱雯,冯筱巍,等. 基于miR-29b/TGF-β/Smad信号通路探讨复方血栓通对糖尿病视网膜病变大鼠作用的机制分析[J]. 临床和实验医学杂志,2024,23(11):1121-1125. |
| 7 | AHMED H S, THRISHULAMURTHY C J. Advancing Diabetic Retinopathy Diagnosis: Leveraging Optical Coherence Tomography Imaging with Convolutional Neural Networks[J]. Rom J Ophthalmol, 2023, 67(4):398-402. doi:10.22336/rjo.2023.53 |
| 8 | NTENTAKIS D P, CORREA V S M C, NTENTAKI A M, et al. Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(3):717-752. doi:10.1007/s00417-023-06236-5 |
| 9 | WANG F, MAO Y, WANG H, et al. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials[J]. Clin Drug Investig, 2022, 42(1):17-28. doi:10.1007/s40261-021-01110-w |
| 10 | LUO Y, WANG H, WANG L, et al. LncRNA MEG3: Targeting the Molecular Mechanisms and Pathogenic causes of Metabolic Diseases[J]. Curr Med Chem, 2024,31(37):6140-6153. doi:10.2174/0109298673268051231009075027 |
| 11 | DORWEILER T F, SINGH A, GANJU A, et al. Diabetic retinopathy is a ceramidopathy reversible by anti-ceramide immunotherapy[J]. Cell Metab, 2024, 36(7):1521-1533.e5. doi:10.1016/j.cmet.2024.04.013 |
| 12 | 周婧,韩梅. 非奈利酮通过抑制小胶质细胞炎症反应减轻大鼠糖尿病视网膜病变[J]. 中国病理生理杂志,2023,39(8):1483-1490. |
| 13 | 贾鑫,刘英琳,杨赞章,等. 止血明目方对糖尿病视网膜病变大鼠炎症因子和氧化应激的影响[J]. 中国中医眼科杂志,2022,32(4):257-262. |
| 14 | 崔家霖,邢俊艳,王莺洁,等. 糖眼宁调控Nod样受体蛋白3炎症小体通路对糖尿病大鼠视网膜细胞焦亡的影响[J]. 广州中医药大学学报,2022,39(3):605-611. |
| 15 | 杨华,张超. 多巴胺对糖尿病视网膜病变模型大鼠视网膜组织中氧化应激和VEGF表达的影响[J]. 国际生物医学工程杂志,2023,46(4):311-315. |
| 16 | 钟绍金,韩珊颖,黄裕昌. 花色苷对糖尿病视网膜病变模型大鼠视网膜氧化应激损伤拮抗作用研究[J]. 现代中药研究与实践,2023,37(3):21-25. |
| 17 | 杨丹,包玉龙,张世良,等. 蓝莓花青素对糖尿病视网膜病变模型大鼠氧化损伤的修复作用及机制[J]. 河北医药,2023,45(1):44-47. |
| 18 | 梁福珍,樊芳,毕萌,等. 齐墩果酸对糖尿病大鼠视网膜氧化应激反应和视网膜神经节细胞损伤的影响[J]. 眼科新进展,2023,43(7):526-529. |
| 19 | 杨文,宋纯东,陈晨晨,等. 基于NF-κB/COX-2炎症通路探讨益气养阴活血方对糖尿病肾病大鼠肾脏保护作用机制[J]. 中医药学报,2023,51(4):21-26. |
| 20 | 刘思佳,吴堃,任凯强,等. 柚皮素通过抑制NF-κB-iNOS/COX-2通路减轻小鼠糖尿病肝损伤[J]. 中国病理生理杂志,2023,39(3):445-450. |
| 21 | 王苏涵,张乐颖,秦婷婷,等. VEGF在糖尿病视网膜病变破坏血-视网膜屏障机制中的研究新进展[J]. 国际眼科杂志,2024,24(8):1260-1265. |
| 22 | 马慧蕾,赵珺彦. MicroRNA-15b与糖尿病视网膜病变患者外周血VEGF及相关炎症因子的关系[J]. 眼科新进展,2023,43(2):137-141. |
/
| 〈 |
|
〉 |